Literature DB >> 29924226

Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.

Maira Renata Merlotto1, Lucas Oliveira Cantadori2, Delmo Sakabe3, Hélio Amante Miot1.   

Abstract

Hypereosinophilic syndrome is defined as persistent eosinophilia (>1500/µL for more than six months) associated with organ involvement, excluding secondary causes. It is a rare, potentially lethal disease that should be considered in cutaneous conditions associated with hypereosinophilia. We report a case of erythroderma as a manifestation of hypereosinophilic syndrome. A 36-year-old male with no comorbidities presented progressive erythroderma, pruritus, peripheral neuropathy, and eosinophilia in the previous seven months. No mutations were found in FIP1L1/PDGFRA. Patient experienced rapid remission in response to oral prednisone and hydroxyurea. Cutaneous manifestations may be the only evidence of hypereosinophilic syndrome. Genotyping excludes myeloproliferative disease, thereby orienting treatment and prognosis.

Entities:  

Mesh:

Year:  2018        PMID: 29924226      PMCID: PMC6001083          DOI: 10.1590/abd1806-4841.20187419

Source DB:  PubMed          Journal:  An Bras Dermatol        ISSN: 0365-0596            Impact factor:   1.896


  10 in total

1.  A Case of Erythroderma Secondary to Hypereosinophilia.

Authors:  Mohammed Shafi Abdulsalam; Hari Chandana Ghanta; Prabu Pandurangan; Maya Menon; Sheba S K Jacob
Journal:  J Clin Diagn Res       Date:  2016-05-01

2.  Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma.

Authors:  Vikram K Mahajan; Ravinder Singh; Karaninder S Mehta; Pushpinder S Chauhan; Saurabh Sharma; Mrinal Gupta; Ritu Rawat
Journal:  J Dermatol Case Rep       Date:  2014-12-31

3.  Treatment of Hypereosinophilic Syndrome with Cutaneous Involvement with the JAK Inhibitors Tofacitinib and Ruxolitinib.

Authors:  Brett King; Alfred Ian Lee; Jaehyuk Choi
Journal:  J Invest Dermatol       Date:  2016-11-22       Impact factor: 8.551

Review 4.  Current strategies in the management of hypereosinophilic syndrome, including mepolizumab.

Authors:  Lawrence B Schwartz; Javed Sheikh; Anish Singh
Journal:  Curr Med Res Opin       Date:  2010-08       Impact factor: 2.580

5.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Authors:  Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2012-03-28       Impact factor: 10.793

Review 6.  Hypereosinophilic syndrome.

Authors:  Heung R Noh; Gil G Magpantay
Journal:  Allergy Asthma Proc       Date:  2017-01-01       Impact factor: 2.587

Review 7.  Clinical overview of cutaneous features in hypereosinophilic syndrome.

Authors:  Sabine Gisela Plötz; Bettina Hüttig; Birgit Aigner; Christian Merkel; Knut Brockow; Cezmi Akdis; Ulf Darsow; Johannes Ring
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 8.  Refining the definition of hypereosinophilic syndrome.

Authors:  Hans-Uwe Simon; Marc E Rothenberg; Bruce S Bochner; Peter F Weller; Andrew J Wardlaw; Michael E Wechsler; Lanny J Rosenwasser; Florence Roufosse; Gerald J Gleich; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2010-07       Impact factor: 10.793

9.  Dermatologic manifestations of the hypereosinophilic syndrome.

Authors:  J A Kazmierowski; M J Chusid; J E Parrillo; A S Fauci; S M Wolff
Journal:  Arch Dermatol       Date:  1978-04

Review 10.  Hypereosinophilic syndrome.

Authors:  Fred H Hsieh
Journal:  Ann Allergy Asthma Immunol       Date:  2014-04-13       Impact factor: 6.347

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.